Published in PLoS One on September 30, 2014
Efficacy and safety of cord blood-derived dendritic cells plus cytokine-induced killer cells combined with chemotherapy in the treatment of patients with advanced gastric cancer: a randomized Phase II study. Onco Targets Ther (2016) 0.79
Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer: A meta-analysis. Oncotarget (2016) 0.78
Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncoimmunology (2015) 0.77
Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy. Exp Ther Med (2016) 0.75
Synchronous double primary cancer of the lung and nasal vestibule: A case report and literature review. Mol Clin Oncol (2016) 0.75
A Positive Role of Cytokine-Induced Killer Cell Therapy on Gastric Cancer Therapy in a Chinese Population: A Systematic Meta-Analysis. Med Sci Monit (2015) 0.75
Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis. Onco Targets Ther (2017) 0.75
Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. J Cancer Res Clin Oncol (2017) 0.75
FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis. Onco Targets Ther (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med (2012) 2.52
Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res (2012) 2.14
Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.94
Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy (2011) 1.74
Two hundred years of cancer research. N Engl J Med (2012) 1.69
Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol (2009) 1.56
Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res (2009) 1.38
Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res (2013) 1.34
Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy (2009) 1.15
Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy (2012) 1.12
Can the dual-functional capability of CIK cells be used to improve antitumor effects? Cell Immunol (2013) 1.10
Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother (2011) 1.10
Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother (2012) 1.08
Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori (2012) 1.07
Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res (2011) 1.07
Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest (2013) 0.98
Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J Transl Med (2011) 0.97
Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials. PLoS One (2012) 0.95
Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Res (2011) 0.95
An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opin Biol Ther (2014) 0.95
Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treat Rev (2012) 0.93
Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer (2008) 0.93
A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol (2013) 0.92
Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3⁺CD56⁺ subset through the co-culturing dendritic cells. PLoS One (2013) 0.91
Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer (2010) 0.91
Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol (2011) 0.88
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer (2010) 0.88
Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Med Oncol (2013) 0.85
Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. Cancer Invest (2011) 0.80
[Therapeutic efficacy of Traditional Vein Chemotherapy and Bronchial Arterial Infusion Combining with CIKs on III Stage Non-small Cell Lung Cancer.]. Zhongguo Fei Ai Za Zhi (2009) 0.78
[Molecular biology of lung cancer series]. Rev Mal Respir (2010) 0.77
Morroniside-Induced PP2A Activation Antagonizes Tau Hyperphosphorylation in a Cellular Model of Neurodegeneration. J Alzheimers Dis (2016) 0.77